ReviewFrontiers in immunology2019
Lessons to Learn From Low-Dose Cyclosporin-A: A New Approach for Unexpected Clinical Applications.
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 88 citations in OpenAlex.
- Modulation of Nrf2/TNF-α and TLR4/TGF-β1 Signaling Pathways by Nigella Sativa Oil and Echinacea Purpurea Extract Attenuates Cyclosporine A-Induced Nephrotoxicity and Immunotoxicity.Cell biochemistry and biophysics · 2026Article
- Biointegration of a partially decellularized tracheal scaffold in a porcine model - preliminary results.Scientific reports · 2026Article
- Proceedings of the 2025 Division of Translational Toxicology Satellite Symposium.Toxicologic pathology · 2026Article
- CTLA-4-Ig therapy preserves cardiac function following myocardial infarction with reperfusion.Cardiovascular research · 2025Article
- Tetrahydrobiopterin enhances regulatory T- and mast cell proliferation and alters cytokines expression in a murine heart transplant model.Scientific reports · 2025Article
- Development and validation of a machine-learning-based model for identification of genes associated with sepsis-associated acute kidney injury.Frontiers in genetics · 2025Article
- Development of Chronic Thyroiditis During Cyclosporin A Treatment.JCEM case reports · 2024Article
- Th Pathways in Immune-Mediated Skin Disorders: A Guide for Strategic Treatment Decisions.Immune network · 2024Review
- Antigen presentation plays positive roles in the regenerative response to cardiac injury in zebrafish.Nature communications · 2024Article
- Primary and secondary defects of the thymus.Immunological reviews · 2024Review
- Cyclosporine-induced alopecia:a case report, FDA adverse event reporting system analysis and literature assessment.Frontiers in pharmacology · 2024Article
- The Impact of Spironolactone Co-administration on Cyclosporin Initial Dosage Optimization for Pediatric Refractory Nephrotic Syndrome.Current pharmaceutical design · 2024Article
- Cyclosporine A alleviates colitis by inhibiting the formation of neutrophil extracellular traps via the regulating pentose phosphate pathway.Molecular medicine (Cambridge, Mass.) · 2023Article
- Protein kinases: drug targets for immunological disorders.Nature reviews. Immunology · 2023Review
- Cyclosporin A inhibits prostate cancer growth through suppression of E2F8 transcription factor in a MELK‑dependent manner.Oncology reports · 2023Article
- Review
- Long-Term Survival and Induction of Operational Tolerance to Murine Islet Allografts by Co-Transplanting Cyclosporine A Microparticles and CTLA4-Ig.Pharmaceutics · 2023Article
- Differential dose-response effect of cyclosporine A in regulating apoptosis and autophagy markers in MCF-7 cells.Inflammopharmacology · 2023Article
- Review
- Peptidomics.Nature reviews. Methods primers · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclosporin-A has been known and used for a long time, since its "fast track" approval in the early 80's. This molecule has rapidly demonstrated unexpected immunosuppressive properties, transforming the history of organ transplantation. Cyclosporin's key effect relies on modulation on T-lymphocyte activity, which explains its role in the prevention of graft rejection. However, whether cyclosporin-A exerts other effects on immune system remains to be determined. Until recently, cyclosporin-A was mainly used at a high-dose, but given the drug toxicity and despite the fear of losing its immunosuppressive effects, there is nowadays a tendency to decrease its dose. The literature has been reporting data revealing a paradoxical effect of low dosage of cyclosporin-A. These low-doses appear to have immunomodulatory properties, with different effects from high-doses on CD8+ T lymphocyte activation, auto-immune diseases, graft-vs.-host disease and cancer. The aim of this review is to discuss the role of cyclosporin-A, not only as a consecrated immunosuppressive agent, but also as an immunomodulatory drug when administrated at low-dose. The use of low-dose cyclosporin-A may become a new therapeutic strategy, particularly to treat cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.